Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-101 with Androgen Ablation in Newly Diagnosed Metastatic Prostate Cancer
NCT00666666Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2009
- Primary completion
- May 2011
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of r-(-)-gossypol acetic acid in prostate cancer (PCa), sponsored by National Cancer Institute. Primary endpoint: Percentage of Patients With Undetectable Prostate-specific Antigen (PSA) (< 0.2 ng/mL) at 7 months. Started Jul 2009; status: completed.
02
Drugs
r-(-)-gossypol acetic acid
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00666666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00666666.